Beam Therapeutics Announces Closing of Initial Public Offering
11 2월 2020 - 9:41PM
Business Wire
Beam Therapeutics Inc. (Nasdaq:BEAM), a biotechnology company
developing precision genetic medicines through base editing, today
announced the closing of its initial public offering of 12,176,471
shares of common stock, including the exercise in full by the
underwriters of their option to purchase up to 1,588,235 additional
shares of common stock, at a public offering price of $17.00 per
share. The aggregate gross proceeds to Beam Therapeutics from the
offering were approximately $207 million, before deducting
underwriting discounts and commissions and other offering expenses.
All of the shares in the offering were offered by Beam
Therapeutics. Beam Therapeutics’ common stock is listed on The
Nasdaq Global Select Market under the ticker symbol “BEAM.”
J.P. Morgan, Jefferies and Barclays acted as joint book-running
managers for the offering. Wedbush PacGrow acted as lead manager
for the offering.
A registration statement relating to the shares sold in this
offering became effective by the Securities and Exchange Commission
on February 5, 2020. The offering was made only by means of a
prospectus. Copies of the final prospectus relating to this
offering may be obtained from J.P. Morgan Securities LLC, c/o
Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood,
NY 11717, telephone: (866) 803-9204, or by emailing
prospectus-eq_fi@jpmchase.com; Jefferies LLC, 520 Madison Avenue,
2nd Floor, New York, NY 10022, Attention: Equity Syndicate
Prospectus Department, by telephone at 877-821-7388 or by email at
prospectus_department@jefferies.com; or Barclays Capital Inc.,
Attention: Broadridge Financial Solutions, 1155 Long Island Avenue,
Edgewood, NY 11717, telephone: 1-888-603-5847, or email:
Barclaysprospectus@broadridge.com.
This press release shall not constitute an offer to sell or a
solicitation of an offer to buy these securities, nor shall there
be any sale of these securities in any state or other jurisdiction
in which such offer, solicitation or sale would be unlawful prior
to the registration or qualification of these securities under the
securities laws of any such state or other jurisdiction.
About Beam Therapeutics
Beam Therapeutics (Nasdaq:BEAM) is a biotechnology company
developing precision genetic medicines through the use of base
editing. Beam’s proprietary base editors create precise,
predictable and efficient single base changes, at targeted genomic
sequences, without making double-stranded breaks in the DNA. This
enables a wide range of potential therapeutic editing strategies
that Beam is using to advance a diversified portfolio of base
editing programs. Beam is a values-driven organization focused on
its people, cutting-edge science, and a vision of providing
life-long cures to patients suffering from serious diseases.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200211005561/en/
Media: Dan Budwick 1AB dan@1abmedia.com Investors: Monique
Allaire THRUST Strategic Communications monique@thrustsc.com
Beam Therapeutics (NASDAQ:BEAM)
과거 데이터 주식 차트
부터 9월(9) 2024 으로 10월(10) 2024
Beam Therapeutics (NASDAQ:BEAM)
과거 데이터 주식 차트
부터 10월(10) 2023 으로 10월(10) 2024